NAD+ Boosters
NMN for Longevity
NMN reliably raises NAD+ in human blood. Whether that helps people live longer is unknown, and trials of muscle, metabolism and function are mostly null.
NMN is one of the best-known supplements in the longevity aisle, usually sold on a simple story: NAD+ declines with age, NMN raises it, so NMN should slow aging. It’s a tidy chain of logic, the kind that fits nicely on a label. If you’re weighing NMN for longevity, Humanic Blue checked those links one at a time, because each has a different amount of evidence behind it.
Link by link, it comes out like this. Nicotinamide mononucleotide (NMN), an ingredient the body uses to make the cellular-energy molecule NAD+, reliably raises NAD+ levels in human blood, and trials lasting up to 24 weeks have generally found it tolerable at 250 to 2,000 mg a day. But no study has shown that NMN helps people live longer.
A 2026 systematic review of 33 human studies covering NMN and other NAD+ products found inconsistent, often absent effects on outcomes related to health and function. A new 24-week trial in adults aged 65 or older found that 1,250 mg/day raised NAD-related substances in blood but did not improve its primary hearing outcome or physical performance. For living longer and better, NMN remains a biomarker story rather than a demonstrated health-outcome story.
In 2025, the FDA concluded that NMN is not categorically excluded from the US dietary-supplement definition; that was not product approval or an effectiveness finding.
Key Takeaways
- NMN raises NAD+ in human blood.
- Short-term use, from two weeks to six months, has been well tolerated in trials.
- Reviews combining trial results have mostly found no clear benefits for muscle, metabolism, blood pressure or physical function; individual findings are inconsistent.
- Human lifespan evidence doesn’t exist.
- The FDA changed its 2022 position that prior drug investigation excluded NMN from supplement status in September 2025; NMN is not categorically excluded from the supplement definition, but products must still meet other legal requirements.
Rung one: a deficiency to fix?
Some established medical uses of supplements correct something missing, like vitamin B12 in someone who can’t absorb it. NMN doesn’t fit that pattern. It’s an intermediate the body already makes on the way to NAD+, a molecule cells use for energy metabolism and DNA repair.
In a 2021 Science trial, Washington University researchers described NMN availability as one factor that can limit mammalian NAD+ production and noted evidence that aging and obesity can impair this pathway in rodents. The idea is that supplying more raw material restores what aging reduces. That’s a biological rationale, not a demonstrated anti-aging effect in people.
Rung two: what have human trials shown?
Human trials consistently find higher blood NAD+ after NMN, but health-outcome results are inconsistent or absent. Many of the trials are small and short, and several are industry-linked.
The metabolic trial. In that Science study, postmenopausal women with prediabetes and overweight or obesity took 250 mg of NMN a day or placebo for 10 weeks. The muscles’ response to insulin improved with NMN, as measured by a clamp test that controls blood sugar and insulin during testing, but the effect did not extend to liver fat, fasting glucose or insulin. Body composition, blood pressure, blood lipids, grip strength and mitochondrial capacity did not change either. One author disclosed patent-licensing income related to NMN; another was an inventor on an NMN patent application.
The dose trial. A 2023 GeroScience trial randomized healthy middle-aged adults to placebo or 300, 600 or 900 mg a day for 60 days. Blood NAD+ rose in all NMN groups, highest at 600 and 900 mg. Walking distance on a six-minute test improved more with NMN, and self-rated health scores rose. HOMA-IR, an estimate of insulin resistance calculated from fasting blood sugar and insulin, did not change. Three authors were employees of Abinopharm and Aba Chemicals.
The newest older-adult trial. A 2026 randomized trial in npj Aging assigned generally healthy adults aged 65 or older to 1,250 mg/day of NMN or placebo for 24 weeks. NMN substantially raised whole-blood NAD+ and related metabolites, substances involved in its processing in the body. It did not improve the primary hearing outcome or physical-performance measures. Apparent changes in some body-composition, blood-fat and dietary measures were no longer statistically significant after researchers accounted for the many comparisons they had made. One NMN participant stopped treatment after liver enzymes that were already elevated rose further; the investigators considered supplement-related injury unlikely. The manufacturer funded the trial, supplied NMN and employed three authors. The trial showed that NMN changed the blood markers it was meant to change, without demonstrating improved hearing or physical performance.
What the pooled evidence shows. Single trials pull in different directions. Reviews that combine their results help show the overall pattern:
A 2026 review of 15 randomized trials found no clear effect on weight, blood sugar, cholesterol or top-number blood pressure, although bottom-number blood pressure dipped slightly. A muscle review in older adults found no significant improvement in muscle mass, grip, walking speed or chair-stand performance. And a broader review of 33 human studies reached the recurring conclusion: NMN and related products raise NAD+ markers, while functional and metabolic benefits remain inconsistent or absent. See the reviews side by side
The muscle review, led by Konstantinos Prokopidis with geriatric-medicine co-authors, therefore did not support NMN or NR for preserving muscle mass and function in older adults. The metabolic review treated its small blood-pressure finding as preliminary and in need of larger, longer trials.
Which measured benefit would matter beyond a rise in blood NAD+?
Rung three: observational evidence
There isn’t any to speak of. No large cohort has followed NMN users over years to compare disease rates or deaths. That’s common for newer supplements, but it means there’s no real-world signal, positive or negative, to set beside the trials.
Rung four: mice and mechanisms
Most of the enthusiasm comes from here. In a 2016 Cell Metabolism study, Shin-ichiro Imai’s group at Washington University gave normal mice NMN for 12 months. The researchers reported that NMN curbed the weight gain that comes with age in mice, boosted energy metabolism and physical activity, and improved insulin sensitivity and blood lipids. The paper reported healthspan measures, not a longer lifespan.
The lifespan claims that circulate online are thinner still. A 2024 study in Food & Function reported longer survival in Zmpste24-knockout mice given NMN. This genetically engineered premature-aging model is useful for research, but it is not normal mouse aging, let alone human aging. The 2026 human-and-rodent systematic review found clear effects on NAD+ markers but inconclusive clinical effectiveness for anti-aging or wellness outcomes.
What changed in NMN regulation?
NMN’s US status changed twice in three years. In late 2022, the FDA said NMN was excluded from the definition of a dietary supplement because it had been authorized for investigation as a drug. Trade groups petitioned the agency to reconsider that interpretation.
On September 29, 2025, the FDA changed course in its petition response. The agency said it had evidence that NMN was marketed as a US dietary supplement as early as 2017, before it was authorized for drug investigation, and concluded that NMN was not excluded under the statute’s drug-preclusion clause.
That conclusion is narrower than “FDA approved NMN.” NMN remains a new dietary ingredient, and a product must still comply with applicable notification, safety, manufacturing and labeling requirements. The FDA’s public notification list now includes NMN submissions and agency response dates, including a January 2026 response. The classification decision did not establish that NMN is effective or approve an anti-aging claim.
What separates permission to sell NMN as a supplement from evidence that it extends life?
What’s Interesting
NMN is a clear example of the distance between a biomarker and an outcome. NAD+ goes up reliably, and it’s measurable in blood within weeks. Whether that translates into living longer is a separate question, and it’s the one no trial has asked. It’s a bit like confirming the package was delivered without yet knowing whether anyone used what was inside. The regulatory back-and-forth also shows how supplement law works. The fight was over which came first, the supplement sales or the drug investigation, not whether NMN helps.
What This Means in Practice
For most people interested in living longer and better, the NMN evidence supports a narrow reading.
- A higher NAD+ reading is a biomarker result. Trials repeatedly found that change, but it is not a guarantee for an individual or a demonstrated health benefit.
- Trial doses have ranged from 250 to 2,000 mg a day for up to 24 weeks. That does not establish a recommended dose, and longer safety remains uncertain.
- Identity and purity differ from effectiveness. Third-party testing of a product’s contents does not establish a health benefit.
- Bring it to your medication review if you take prescription drugs, are pregnant or breastfeeding, or have cancer or a cancer history. The trials so far have enrolled mostly healthy adults or people with early metabolic risk.
- The outcome matters. The guide to longevity supplements with human evidence separates changes in lab markers from strength, disease and mortality outcomes.
It’s also worth noticing who the trials enrolled. The Science study tested postmenopausal women with prediabetes and overweight or obesity, the dose trial tested healthy middle-aged adults, and the muscle review covered older adults. A result in one of those groups doesn’t automatically carry over to another, or to someone managing several prescriptions.
A primary care clinician or pharmacist can check for interactions. A registered dietitian can help compare NMN with dietary sources of vitamin B3.
Bottom Line
NMN raises NAD+ in human blood and has been generally tolerated for up to about six months. But pooled trials have not shown meaningful benefits for muscle or metabolic outcomes, and the newest older-adult trial raised NAD-related substances in blood without improving hearing or physical performance. No study has tested whether NMN helps people live longer. Animal findings—including longer survival in a premature-aging mouse strain—cannot answer that human question. The FDA’s 2025 decision removed a categorical legal exclusion; it did not approve NMN or establish effectiveness. Longer trials measuring outcomes people care about are still the missing piece.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01What would you want to know before putting "NMN for Longevity" into the same conversation as sleep, food, movement, and medical care?
- 02Which evidence boundary stood out most: lifespan, function, symptoms, biomarkers, dose, safety, or who was actually studied?
- 03What question would help keep a supplement conversation grounded instead of turning it into a shopping list?
Extra Insights & Sources
The evidence summaries and linked sources behind this article. In the summaries below, a null result means no statistically clear effect was found; it does not prove that no effect is possible. The drug-preclusion clause is the legal rule about excluding certain ingredients investigated as drugs from the dietary-supplement definition.
What We Know
- NMN raises blood NAD+ in a dose-related way, with the 2023 dose trial finding the highest levels at 600–900 mg a day. Established.
- Short-term safety is broadly reassuring: the 2026 meta-analysis found no pooled increase in overall or serious adverse events, and the newest 24-week trial reported no significant treatment-related safety signal. Supported, for up to 24 weeks; not long-term proof.
- Muscle mass and strength in older adults don’t improve with NMN, based on pooled trials. Supported (null).
- Glucose, HbA1c and cholesterol don’t change meaningfully with NMN, based on pooled trials. Supported (null).
What We Don’t Know
- Whether NMN extends human lifespan. Unknown. No trial has measured it, and none has measured death or disease outcomes.
- Long-term safety beyond about six months. Unknown.
- Whether higher blood NAD+ reaches the tissues that matter and changes how they age. Unknown.
- Whether results from specific trial formulations apply to retail products with different sourcing and manufacturing controls. Unknown.
The pooled evidence side by side
RCT means randomized controlled trial, where participants are assigned by chance to different treatments. HbA1c reflects average blood sugar over roughly three months; lipids are blood fats. Systolic and diastolic pressure are the top and bottom blood-pressure numbers. A statistically significant result is one that meets the study’s threshold for distinguishing a signal from chance; it does not by itself establish a meaningful health benefit.
| Review | What it pooled | What it found |
|---|---|---|
| Yang et al., Nutrients, 2026 | 15 RCTs; 250–2,000 mg/day; 14 days to 24 weeks | No increase in adverse events or liver enzymes; no effect on weight, glucose, HbA1c, lipids or systolic blood pressure; small drop in diastolic pressure |
| Prokopidis et al., J Cachexia Sarcopenia Muscle, 2025 | RCTs of NMN or NR in adults with mean age 60.9–83 | No significant effect of NMN on muscle mass, grip strength, gait speed or chair-stand time |
| Gallagher & Emmanuel, Ageing Res Rev, 2026 | 33 human and 80 rodent studies of NAD+ boosters | Blood NAD+ markers increased in humans; effects on physical function and metabolism were inconsistent and often absent |
Sources
- Gallagher & Emmanuel, Ageing Research Reviews (2026), PMID 41655607 — Systematic review of 33 human interventions and 80 rodent studies involving NAD+ precursors (ingredients the body uses to make NAD+) or NAD+ given by injection or infusion. Supports reliable changes in NAD+ markers but inconsistent or absent benefits for physical function or metabolism and the absence of human longevity evidence; the interventions and populations varied widely.
- Yoshino et al., Science (2021), PMID 33888596 — Ten-week randomized trial of 250 mg/day in 25 postmenopausal women with prediabetes and overweight or obesity. Supports improved muscle insulin sensitivity and the null secondary outcomes; small, population-specific, and affected by patent-related author interests.
- Yi et al., GeroScience (2023), PMID 36482258 — Sixty-day randomized trial in 80 healthy middle-aged adults assigned to placebo or 300, 600 or 900 mg/day. Supports increased blood NAD+, six-minute-walk and self-rated-health findings and null HOMA-IR result; three authors were employed by ingredient companies and follow-up was short.
- Igarashi et al., npj Aging (2026), DOI 10.1038/s41514-026-00482-7 — Twenty-four-week randomized trial in 60 adults aged 65 or older (31 NMN, 29 placebo at baseline; 58 assessed at week 24) using 1,250 mg/day. Supports increases in NAD-related substances in blood and null hearing/physical-performance results. Apparent changes in additional measurements were no longer statistically significant after accounting for the many comparisons made; the manufacturer funded the work, supplied NMN and employed three authors.
- Yang et al., Nutrients (2026), PMID 42514320 — Meta-analysis of 15 randomized trials using 250–2,000 mg/day for 14 days to 24 weeks. Supports pooled tolerability and mostly null weight, glucose, HbA1c, lipid and systolic-pressure results; trials were small and short, and the small diastolic-pressure signal is preliminary.
- Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle (2025), PMID 40275690 — Meta-analysis of NMN/NR trials in adults with mean ages 60.9–83 years. Supports null NMN effects on muscle mass, grip strength, gait speed and chair-stand performance; based on few small trials.
- Mills et al., Cell Metabolism (2016), PMID 28068222 — Twelve-month NMN experiment in normally aging mice. Supports reported metabolic and activity-related healthspan measures, not longer lifespan; animal findings cannot establish human benefit.
- Gu et al., Food & Function (2024), PMID 38445897 — NMN experiment in Zmpste24-knockout mice. Supports the reported survival extension only in a genetically engineered premature-aging model, not normal mice or humans.
- FDA response to the NPA/ANH petition, September 29, 2025 — Primary regulatory source for FDA’s revised interpretation: NMN is not excluded from the dietary-supplement definition under the drug-preclusion clause because the agency found evidence of US supplement marketing before drug-investigation authorization. The letter does not approve a product, establish safety/effectiveness or waive other legal requirements.
- FDA New Dietary Ingredient notification list — Current public list of reviewed notifications and response dates, including NMN entries. A listing or response date is not itself evidence of anti-aging efficacy.
Photo credits
Images from Pexels.
- featured: Photo by RDNE Stock project — original Pexels photo.
- inline-1: Photo by cottonbro studio — original Pexels photo.
- inline-2: Photo by Pixabay — original Pexels photo.
Leave a Reply